Comparable efficacy of extraoral and intraoral photobiomodulation in preventing oral mucositis during high-dose methotrexate therapy in pediatric oncology: A single-blind randomized controlled trial
Oct 2026· Supportive Care in Cancer· Vol 34· 0 citations· 41 references
Medicine
TL;DR
Extraoral PBM demonstrated comparable effectiveness to intraoral for OM prevention in pediatric patients undergoing HDMTX chemotherapy, while reducing application time.
Abstract
This prospective randomized controlled clinical study compared intraoral (IO) and extraoral (EO) photobiomodulation (PBM) for the prevention of chemotherapy-induced oral mucositis (OM) in pediatric oncology patients. A total of 155 patients (1–18 years), receiving high-dose methotrexate (HDMTX) for leukemia, lymphoma, or osteosarcoma, were randomized to PBM-IO (n = 73) or PBM-EO (n = 82). Preventive PBM was administered daily from hospital admission through discharge. Both protocols used red light with equivalent dosimetry (660 nm, 100 mW, 1 J per point). PBM-EO required 30 s/session, whereas PBM-IO required approximately 6 min, excluding patient handling time. OM occurrence, severity (WHO scale), plaque index, and pain (numeric rating scale) were assessed on days 0, 3, 5, and 10 after HDMTX infusion. The overall OM occurrence was 35.5%, with no significant difference between PBM-IO (41.1%) and PBM-EO (30.5%) groups (p = 0.168). No statistically significant differences were observed between groups for OM severity, pain, salivary pH, or plaque index at any time point (p > 0.05). Multivariable ordinal logistic regression demonstrated that PBM modality was not independently associated with OM severity. As expected, increasing age (OR = 1.14; 95% CI: 1.04–1.25; p = 0.004) and higher HDMTX dose (OR = 1.24; 95% CI: 1.03–1.49; p = 0.021) were significantly associated with greater OM severity. Median pain scores remained 0 at all assessment points in both groups. Extraoral PBM demonstrated comparable effectiveness to intraoral for OM prevention in pediatric patients undergoing HDMTX chemotherapy, while reducing application time.
365
Background:
Radiation dermatitis is nearly universal among patients with HNC receiving radiotherapy, with 73-80% developing grade ≥2 and 14-25% developing grade ≥3 toxicity in contemporary trials. Recovery typically occurs 2-4 weeks after treatment ends, with complete resolution by 6-8 weeks. PBM has demons...
R. Ferrari, B. Ferrari, Leticia Araujo et al.· JCO Oncology Practice· 0 citations
Although caregivers more frequently perceived IO-PBMT as providing better pain control, these subjective perceptions did not correspond to differences in the clinical occurrence or severity of OM between treatment modalities, and EO-PBMT represents a feasible and well-accepted approach for supportive care in pediatric...
Isabela de Oliveira Plugge Freitas, Giovanna Leal Klein Renz, Isabela Schuartz et al.· Supportive Care in Cancer· 0 citations
Objectives: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) compared to observation in managing low-grade squamous intraepithelial lesions (LSILs) with high-risk HPV infection. Methods: We conducted a retrospective cohort study involving 608 patients with pathologically confirmed LSILs and Hr-HP...
Xiao-Yun Wang, Jian-Xia Huang, Qiong-Hua He et al.· Pharmaceutics· 0 citations
Purpose To observe the clinical efficacy and influencing factors of 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) in treatment oral leukoplakia (OL), so as to provide therapeutic references for clinical application. Materials and Methods After optimizing the 5-ALA-PDT treatment process, 31 OL patients were loc...
Jin-Jin Zhao, Yang Cai, Yong-Xin Hu et al.· Oral Health & Preventive Den...· 0 citations
Radiation-induced neck fibrosis (RIF-N) significantly impairs function, cosmesis, and quality of life in head and neck cancer (HNC) survivors. Current management options are limited and largely experimental. Photobiomodulation therapy (PBMT), a safe, noninvasive intervention, shows antifibrotic potential in early s...
Rachita Gururaj, M. Janaki, Vinay M. D. Prabhu et al.· Rehabilitation Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.